Clinical trial · Interventional
DC-CIK Immunotherapy Plus Chemotherapy vs Chemotherapy Alone in the Adjuvant Treatment of Stage III Colorectal Cancer
Randomized Controlled Trial Comparing DC-CIK Immunotherapy Combined With Adjuvant Chemotherapy and Adjuvant Chemotherapy Alone in Stage III Colorectal Cancer.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Stage III colorectal cancer constitutes more than half of the colorectal patients, and the prognosis does not improve much recently although varies of adjuvant drugs have been tried. DC-CIK immunotherapy has been proved to improve survival in cancer patients, but its role in stage III colorectal cancer patients stains unclear. The investigators study will focus on the efficacy and safety of DC-CIK immunotherapy plus chemotherapy in the adjuvant treatment of stage III colorectal cancer, compared with chemotherapy alone.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| DC-CIK | Biological | — | UNRESOLVED |
| Fluorouracil | Drug | Fluorouracil | ALIAS |
| Leucovorin | Drug | Leucovorin | ALIAS |
| Oxaliplatin | Drug | Oxaliplatin | ALIAS |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- DC-CIK Immunotherapy Plus Chemotherapy
- description
- Stage III Colon Cancer patients after radical operation and adjuvant chemotherapy will receive 12 cycles of DC-CIK therapy in this group
- interventionNames
- Drug: Fluorouracil
- Drug: Oxaliplatin
- Drug: Leucovorin
- Biological: DC-CIK
- type
- ACTIVE_COMPARATOR
- label
- Chemotherapy Alone
- description
- Stage III Colon Cancer patients after radical operation and adjuvant chemotherapy alone.
- interventionNames
- Drug: Fluorouracil
- Drug: Oxaliplatin
- Drug: Leucovorin
Primary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Stage III colon cancer * Undergone complete resection of primary tumor * Completed standard adjuvant chemotherapy * ECOG performancer status 0-2 * Adequate hematologic, hepatic and renal functions Exclusion Criteria: * HIV positive or other Immunodeficiency disease * Uncontrolled hypertension * History of recent cancers in the past 5 years * Patients with previous or concurrent malignancy or any anti-cancer therapy * Patients who were allergic to platinum drugs or fluorouracil * Pregnant patients
References
Publications (0)
Data not yet available